CBC (Cannabichromene) is one of the minor and lesser known cannabinoids found in the cannabis plant. Isolated for the first time in 1966, this cannabinoid has never been thoroughly studied in chemical and biological terms, also and above all for its much lower concentration in the plant compared to the more famous THC and CBD in cannabis.
A new paper brings it back to the center of attention by identifying its potential therapeutic characteristics in the treatment of respiratory distress syndrome, which has returned to the news again with the appearance of Covid-19. Patients affected by this disease show very low blood oxygenation, which is difficult to increase even through external respiratory support.
This study highlights how CBC-based inhalation treatment can improve symptoms and blood oxygenation in patients with ARDS (Acute respiratory distress syndrome), concluding how a therapy based on this cannabinoid can and should be taken into consideration and studied. more, in order to have a new ally in the fight against this terrible disease.
The development of research of this type is also due to the breeding and the creation of new strains with significant percentages of cannabinoids, which in the case of CBC are unfortunately rare.
Below is the link for the complete study